Clinical Trial Update: A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing guselkumab to secukinumab for moderate to severe plaque psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Guselkumab (guselkumab)
• Secukinumab (secukinumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-10-01